In Brief: OrthoLogic
This article was originally published in The Gray Sheet
Executive SummaryOrthoLogic: Expanding patient enrollment in clinical trials of the OrthoLogic 1000 bone growth stimulator "to establish conclusive statistical significance" of the device's effectiveness in treating delayed union fractures, the company says. Results from the first 106 fractures showed that 62.5 % of the patients with OrthoLogic 1000 devices healed as opposed to 55.2% of the subjects that received placebo devices. While the data obtained from the study shows a positive effect, "the healing rate in the placebo group was greater than originally anticipated," according to an OrthoLogic press release. OrthoLogic received PMA approval for the product to treat nonunion fractures in March of 1994 ("The Gray Sheet" March 14, 1994, p. 4). ..
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.